Patrick Neven

Research interests

Publications

• Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.00338

• Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00694-5

• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

  Annals of Oncology · 2021 · 10.1016/j.annonc.2021.09.015

• A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01323-8

• Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(21)00034-6

• Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.353

• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.4782

• Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911149

• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.9909

• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.7585

• Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent

  PLoS Medicine · 2016 · 10.1371/journal.pmed.1002105

• Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

  Breast Cancer Research and Treatment · 2015 · https://doi.org/10.1007/s10549-015-3287-5

• Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

  Nature Genetics · 2015 · 10.1038/ng.3242

• Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

  Nature Communications · 2014 · https://doi.org/10.1038/ncomms5999

• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

  Annals of Oncology · 2014 · 10.1093/annonc/mdu456

• Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.45.6335

• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

  Annals of Oncology · 2012 · 10.1093/annonc/mds277

• CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

  JNCI Journal of the National Cancer Institute · 2012 · 10.1093/jnci/djs125

• Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70270-4

• Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium

  Human Molecular Genetics · 2011 · https://doi.org/10.1093/hmg/ddr228

• Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

  JNCI Journal of the National Cancer Institute · 2010 · 10.1093/jnci/djq526

• Lasofoxifene in Postmenopausal Women with Osteoporosis

  New England Journal of Medicine · 2010 · 10.1056/nejmoa0808692

• Breast cancer in pregnancy: Recommendations of an international consensus meeting

  European Journal of Cancer · 2010 · 10.1016/j.ejca.2010.09.010

• Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.17.0829

• Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.9453

• Endometrial cancer

  The Lancet · 2005 · https://doi.org/10.1016/s0140-6736(05)67063-8

• Endometriosis and the development of malignant tumours of the pelvis. A review of literature

  Best Practice & Research Clinical Obstetrics & Gynaecology · 2004 · 10.1016/j.bpobgyn.2003.03.001

Current projects

No projects listed.